Which patients are you utilizing subcutaneous PD-1/L1 inhibitors instead of the intravenous formulation?

The only one of these agents I use in my Breast Oncology practice is pembrolizumab. I would be comfortable substituting SC for IV pembrolizumab if covered by insurance, but I have not yet had an instance where I have tried this.